Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUG252 in Mild-to-Moderate SLE
NCT05866861Phase 1Completed
- Sponsor
- Cugene Inc.
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing CUG252 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 64 days. Started Apr 2023; status: completed.
02
Drugs
CUG252
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05866861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866861.